Page last updated: 2024-08-16

temozolomide and everolimus

temozolomide has been researched along with everolimus in 30 studies

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (6.67)29.6817
2010's20 (66.67)24.3611
2020's8 (26.67)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Alemany, R; Alonso, MM; Bekele, NB; Fueyo, J; Gomez-Manzano, C; Jiang, H; Piao, Y; Yung, WK1
Belohlavek, C; Christmann, M; Jöst, E; Kaina, B; Lennerz, V; Naumann, SC; Roos, WP; Schmidt, CW1
Eriksson, B1
Brown, PD; Buckner, JC; Galanis, E; Giannini, C; Jaeckle, KA; McGraw, S; Peller, PJ; Sarkaria, JN; Uhm, JH; Wu, W1
Borson-Chazot, F; Ducray, F; Favrel, V; Honnorat, J; Jouanneau, E; Raverot, G; Trouillas, J; Wierinckx, A1
Easaw, J; Eisenhauer, E; Kavan, P; Lwin, Z; Macdonald, D; Macneil, M; Mason, WP; McIntosh, L; Thiessen, B; Urva, S1
Reidy-Lagunes, D; Thornton, R1
Brinker, BT; Hainsworth, JD; Shepard, GC; Shih, KC; Spigel, DR; Tillinghast, GW1
Igarashi, H; Ito, T; Jensen, RT; Takayanagi, R1
Allred, JB; Creagan, ET; Dronca, RS; Kaur, JS; Lieser, EA; Maples, WJ; Marchello, BT; Markovic, SN; Moore, TD; Nevala, WK; Perez, DG; Pockaj, BA; Thompson, M1
Bischoff, P; Burckel, H; Josset, E; Noël, G1
Chinnaiyan, P; Corn, BW; Dipetrillo, TA; Mehta, MP; Rojiani, AM; Wen, PY; Wendland, M; Won, M1
Allen, J; Blaszkowsky, L; Chan, JA; Gonzalez, M; Kulke, MH; Meyerhardt, J; Regan, E; Ryan, DP; Stuart, K; Wadlow, R; Zheng, H; Zhu, AX1
Ferolla, P1
Bischoff, P; Burckel, H; Denis, JM; Gueulette, J; Josset, E; Noël, G; Slabbert, J1
Anderson, SK; Brown, PD; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Ligon, KL; Ma, DJ; McGraw, S; Peller, PJ; Sarkaria, JN; Schiff, D; Uhm, JH1
Abdel-Rahman, O; Fouad, M1
Astorgues-Xerri, L; Bekradda, M; Berenguer-Daizé, C; Cayol, M; Cvitkovic, E; Lokiec, F; MacKenzie, S; Noel, K; Odore, E; Ouafik, L; Rezai, K; Riveiro, ME1
Arnal, AV; Donovan, LE; Odia, Y; Wang, SH1
Ahluwalia, MS; Ashby, LS; Chinnaiyan, P; Fiveash, JB; Kee, AY; Malone, SC; Mehta, MP; Michael Yu, HH; Mohile, NA; Rojiani, AM; Shih, HA; Stella, PJ; Stieber, VW; Wen, PY; Wendland, MM; Werner-Wasik, M; Won, M1
Andreasi, V; April-Monn, SL; Capurso, G; Di Domenico, A; Doglioni, C; Falconi, M; Gloor, B; Kim-Fuchs, C; Maire, R; Marinoni, I; Muffatti, F; Partelli, S; Perren, A; Schiavo Lena, M; Skowronska, M; Trippel, M; Wiedmer, T; Zatelli, MC1
Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D1
Dagohoy, CG; Dasari, A; Halperin, DM; Lam, M; Rogers, JE; Yao, JC1
Dong, L; Jiang, X; Meng, L; Qu, C; Wang, B; Wang, H; Wei, J; Xin, Y; Zhao, Q1
Chen, AP; Das, B; Doroshow, JH; Foster, JC; Karlovich, C; Konaté, MM; Kummar, S; Leong, S; Li, MC; Lih, CJ; Meric-Bernstam, F; Moore, N; O'Sullivan Coyne, G; Palmisano, A; Piekarz, R; Polley, E; Raghav, KPS; Rosenberger, CL; Rubinstein, LV; Simon, R; Simpson, M; Sims, D; Waqar, S; Williams, PM; Zhao, Y1
Colao, A; Faggiano, A; Ferraù, F; Lania, A; Modica, R; Rubino, M1
Huang, GL; Li, ZY; Que, TS; Yi, GZ; Zhu, TC1
Geer, EB; Lala, N; Lin, AL; Magge, R; Page-Wilson, G; Tabar, V; Young, RJ1

Reviews

10 review(s) available for temozolomide and everolimus

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
    Current opinion in oncology, 2010, Volume: 22, Issue:4

    Topics: Antineoplastic Agents; Capecitabine; Dacarbazine; Deoxycytidine; Drug Therapy; Everolimus; Fluorouracil; Humans; Indoles; Neuroendocrine Tumors; Octreotide; Pyrroles; Sirolimus; Sunitinib; Temozolomide; Treatment Outcome

2010
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different?
    Current oncology reports, 2012, Volume: 14, Issue:3

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes

2012
[Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
    Fukuoka igaku zasshi = Hukuoka acta medica, 2012, Volume: 103, Issue:7

    Topics: Antineoplastic Agents; Dacarbazine; Digestive System Surgical Procedures; Everolimus; Humans; Immunosuppressive Agents; Indoles; Japan; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Somatostatin; Streptozocin; Sunitinib; Temozolomide

2012
Medical treatment of advanced thoracic neuroendocrine tumors.
    Thoracic surgery clinics, 2014, Volume: 24, Issue:3

    Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Dacarbazine; Everolimus; Humans; Neuroendocrine Tumors; Sirolimus; Temozolomide; Thoracic Neoplasms

2014
Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
    Future oncology (London, England), 2015, Volume: 11, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Dacarbazine; Everolimus; Humans; Neuroendocrine Tumors; Octreotide; Temozolomide; Thalidomide

2015
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
    Current treatment options in oncology, 2020, 08-29, Volume: 21, Issue:11

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecitabine; Carcinoid Tumor; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Everolimus; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymph Node Excision; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pneumonectomy; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Temozolomide; Watchful Waiting

2020
Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.
    Annals of palliative medicine, 2021, Volume: 10, Issue:7

    Topics: Adult; Brain Neoplasms; Dacarbazine; Everolimus; F-Box-WD Repeat-Containing Protein 7; Humans; Male; Melanoma; Mutation; Temozolomide

2021
Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future Approaches.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Capecitabine; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Everolimus; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neuroendocrine Tumors; Pancreatic Neoplasms; Quality of Life; Radioisotopes; Somatostatin; Temozolomide; Treatment Outcome

2021
The treatment of aggressive prolactinomas with everolimus.
    Pituitary, 2023, Volume: 26, Issue:4

    Topics: Dopamine Agonists; Everolimus; Humans; Pituitary Neoplasms; Prolactinoma; Temozolomide

2023

Trials

9 trial(s) available for temozolomide and everolimus

ArticleYear
North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed glioblastoma multiforme.
    International journal of radiation oncology, biology, physics, 2011, Oct-01, Volume: 81, Issue:2

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Everolimus; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Positron-Emission Tomography; Radiopharmaceuticals; Sirolimus; Temozolomide

2011
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study.
    Investigational new drugs, 2012, Volume: 30, Issue:6

    Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Drug Combinations; Everolimus; Female; Glioblastoma; Humans; Immunosuppressive Agents; Male; Middle Aged; PTEN Phosphohydrolase; Sirolimus; Temozolomide; Young Adult

2012
Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
    Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bevacizumab; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Everolimus; Female; Glioblastoma; Humans; Immunosuppressive Agents; Male; Middle Aged; Sirolimus; Temozolomide; Young Adult

2012
Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.
    American journal of clinical oncology, 2014, Volume: 37, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Everolimus; Female; Humans; Induction Chemotherapy; Male; Melanoma; Middle Aged; Sirolimus; Skin Neoplasms; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A

2014
RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
    International journal of radiation oncology, biology, physics, 2013, Aug-01, Volume: 86, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Dose Fractionation, Radiation; Everolimus; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sirolimus; Temozolomide

2013
A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
    Cancer, 2013, Sep-01, Volume: 119, Issue:17

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Prospective Studies; Sirolimus; Temozolomide; Treatment Outcome

2013
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K.
    Neuro-oncology, 2015, Volume: 17, Issue:9

    Topics: Antineoplastic Agents; Brain Neoplasms; Dacarbazine; Drug Therapy, Combination; Everolimus; Glioblastoma; Humans; Positron-Emission Tomography; Prognosis; Survival Analysis; Temozolomide; TOR Serine-Threonine Kinases; Treatment Outcome

2015
A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913.
    Neuro-oncology, 2018, 04-09, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Everolimus; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Survival Rate; Temozolomide; Young Adult

2018
Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial.
    JCO precision oncology, 2021, Volume: 5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carboplatin; DNA, Neoplasm; Double-Blind Method; Everolimus; Female; Gene Expression Profiling; Humans; Male; Middle Aged; Molecular Diagnostic Techniques; Neoplasms; Pyrazoles; Pyridones; Pyrimidinones; Temozolomide; Young Adult

2021

Other Studies

11 other study(ies) available for temozolomide and everolimus

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
    Cancer gene therapy, 2007, Volume: 14, Issue:8

    Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Dacarbazine; Everolimus; Glioma; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Oncolytic Virotherapy; Sirolimus; Temozolomide

2007
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
    British journal of cancer, 2009, Jan-27, Volume: 100, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Collagen Type XI; Dacarbazine; DNA Breaks, Double-Stranded; DNA Mismatch Repair; DNA Modification Methylases; DNA Repair Enzymes; Enzyme Activation; Everolimus; Humans; Melanoma; Necrosis; Phosphorylation; Sirolimus; Temozolomide; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2009
New targeted therapies in pituitary carcinoma resistant to temozolomide.
    Pituitary, 2012, Volume: 15, Issue:1

    Topics: Dacarbazine; Drug Resistance, Neoplasm; Everolimus; Humans; Male; Middle Aged; Pituitary Neoplasms; Sirolimus; Temozolomide

2012
The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line.
    Anticancer research, 2013, Volume: 33, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Brain Neoplasms; Cell Proliferation; Cesium Radioisotopes; Dacarbazine; Drug Synergism; Everolimus; Flow Cytometry; Gamma Rays; Glioblastoma; Humans; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Tumor Cells, Cultured

2013
Combination of the mTOR inhibitor RAD001 with temozolomide and radiation effectively inhibits the growth of glioblastoma cells in culture.
    Oncology reports, 2015, Volume: 33, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; Dose-Response Relationship, Radiation; Everolimus; Gamma Rays; Glioblastoma; Histones; Humans; Linear Energy Transfer; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases

2015
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
    International journal of cancer, 2016, 11-01, Volume: 139, Issue:9

    Topics: Acetanilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; Drug Synergism; Everolimus; Gene Expression Regulation, Neoplastic; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Irinotecan; Mice; Temozolomide; Xenograft Model Antitumor Assays

2016
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy.
    CNS oncology, 2016, Volume: 5, Issue:4

    Topics: Adenoma; Adrenocorticotropic Hormone; AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Brain; Brain Neoplasms; Capecitabine; Dacarbazine; Everolimus; Female; Humans; Ki-67 Antigen; Magnetic Resonance Imaging; Middle Aged; Mutation; Pituitary Neoplasms; Protein Serine-Threonine Kinases; Temozolomide

2016
Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors.
    Neuroendocrinology, 2021, Volume: 111, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cryopreservation; Drug Screening Assays, Antitumor; Everolimus; Humans; Islets of Langerhans; Neuroendocrine Tumors; Pancreatic Neoplasms; Primary Cell Culture; Proof of Concept Study; Sunitinib; Temozolomide

2021
Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
    Neuroendocrinology, 2022, Volume: 112, Issue:1

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Everolimus; Female; Fluorouracil; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Retrospective Studies; Streptozocin; Temozolomide; Treatment Outcome; Young Adult

2022
Individualized combination therapies based on whole-exome sequencing displayed significant clinical benefits in a glioblastoma patient with secondary osteosarcoma: case report and genetic characterization.
    BMC neurology, 2022, Oct-21, Volume: 22, Issue:1

    Topics: Bone Neoplasms; Brain Neoplasms; Everolimus; Exome Sequencing; Female; Glioblastoma; Humans; Middle Aged; Mutation; Osteosarcoma; Temozolomide

2022